{"id":"W3211568627","doi":"10.1182/blood-2021-146570","title":"Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Fludarabine; Progression-free survival; Neutropenia; Oncology; Ibrutinib; Toxicity; Chemotherapy; Leukemia; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006930668,0.001288836,0.002752437,0.0004767767,0.0008717976,0.001937761,0.001064896,0.002296274,0.003475825],"category_scores_gemma":[0.003771583,0.0004277723,0.003425202,0.0004757398,0.0008734238,0.002091122,0.0008503748,0.004593968,0.0007630672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009821291,"about_ca_system_score_gemma":0.0008821641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001128285,"about_ca_topic_score_gemma":0.001744054,"domain_scores_codex":[0.9981937,0.0009545038,0.0001038248,0.0002560803,0.0001573306,0.0003344931],"domain_scores_gemma":[0.9967207,0.0008380863,0.0007340772,0.0003399264,0.000242599,0.001124543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9608201,0.005279447,0.01055365,0.0001554741,0.002050528,0.0001141615,0.00006192963,0.001088492,0.001766847,0.0001027137,0.00325798,0.01474865],"study_design_scores_gemma":[0.4424334,0.4104228,0.120934,0.0001525465,0.009556796,0.0003727343,0.0001879539,0.005642354,0.003048089,0.001195844,0.005924383,0.0001292485],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872377,0.004445254,0.0004589419,0.0007705456,0.0003708827,0.0006482141,0.003104266,0.00007520857,0.002889016],"genre_scores_gemma":[0.9915357,0.0007034081,0.0002698045,0.0009814274,0.0003886493,0.0005692617,0.004137732,0.00001866989,0.001395335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006930668,"threshold_uncertainty_score":0.03665328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03271177986919534,"score_gpt":0.3020224346088241,"score_spread":0.2693106547396288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}